Drug Database
EP

epoetin alfa (Heberitro / EPO, Heber Biotec)

✓ Approved

Heber Biotec · EPOR · 重组蛋白

什么是 epoetin alfa?

epoetin alfa 是一种重组蛋白,由Heber Biotec研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Heberitro, EPO, Heber Biotec
公司Heber Biotec
药物类别重组蛋白
分子靶点EPOR
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

epoetin alfa 作用于 1 个分子靶点:

EPORerythropoietin receptor (EPO-R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

epoetin alfa 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersNephrogenic anaemia✓ Approved

相关研究文献

PubMedFrontiers in reproductive health2026-11-18

Follitropin alfa versus follitropin alfa/lutropin alfa (rFSH/rLH) in progestin-primed ovarian stimulation: a prospective two-center observational cohort study.

Pabuccu Emre E, Tohma Yusuf Aytac YA, Ozkavukcu Sinan S

The contribution of recombinant LH during progestin-primed ovarian stimulation (PPOS) remains uncertain. We compared recombinant FSH alone (GON) with recombinant FSH plus recombinant LH (PER) in a prospective two-center observational cohort. The full enrolled cohort included 213 women (121 GON; 92 PER), including 11 with day-3 transfer. MII oocyte count was the primary outcome. The primary negative binomial model adjusted for female age, AMH, baseline AFC, previous failed cycles and center. Propensity scores used the same covariates; matching was 1:1, exact within center, using Mahalanobis distance within a logit propensity-score caliper. The per-protocol (PP) population comprised the 202 women whose embryos were cultured to day 5; in the full-cohort (ITT) analysis, the 11 women with day-3 transfer contributed zero day-5 blastocysts. The primary adjusted MII incidence rate ratio (IRR) for PER versus GON was 1.01 (95% CI 0.91-1.11; p = 0.910); the PP IRR was 1.00 (95% CI 0.91-1.11; p = 0.939). The number of MII oocytes was similar in both groups (median 11 in both), and this finding did not change after adjustment for baseline characteristics or after propensity-score matching. PER was associated with more day-5 blastocysts (median 4 vs. 3) and more top-quality blastocysts (median 2 vs. 1), and these differences persisted after adjustment and matching. Positive β-hCG rates after the first frozen embryo transfer were similar (47.6% vs. 43.2%). OHSS was rare (1 PER and 2 GON cases, all mild), and no cycle was canceled. No statistically significant difference in MII count was detected, and equivalence was not established. The higher day-5 blastocyst counts associated with PER may reflect an effect of LH on embryo developmental competence rather than on oocyte yield; this exploratory finding does not establish a causal or clinical benefit and requires confirmation in randomized trials. https://clinicaltrials.gov/study/NCT07348757, NCT07348757.

PMID 43047481
阅读全文 →
PubMedTherapeutic advances in hematology2026-11-18

Real-world effectiveness and usage of rFIXFc prophylaxis in hemophilia B: Final results from the B-MORE study.

Glosli Heidi H, Al Saleh Mahasen M, Nolan Beatrice B, Allsup David D et al.

Eftrenonacog alfa is an extended half-life recombinant factor IX Fc fusion protein (rFIXFc) approved for the treatment and prevention of bleeding episodes in people with hemophilia B (PwHB). Providing continuous and comprehensive real-world data is crucial to support informed treatment strategies with rFIXFc in routine practice. The B-MORE study was designed to provide further insights into real-world utilization and effectiveness of rFIXFc in PwHB. To describe the final real-world effectiveness and usage data for rFIXFc in PwHB from B-MORE. B-MORE (NCT03901755) was a 24-month prospective, non-interventional study across Europe and the Middle East. Eligible patients had hemophilia B and started rFIXFc treatment before or at enrollment, regardless of study participation. Descriptive analyses were performed for patients who received ≥6 months of rFIXFc prophylaxis, either during the prospective period or since rFIXFc initiation (before/at enrollment). Additionally, intrapatient comparisons with prior standard half-life (SHL) FIX prophylaxis were conducted. Endpoints included annualized bleeding rate (ABR), injection frequency, factor consumption, and treatment satisfaction. B-MORE enrolled 151 patients from 29 centers; >80% completed the study. In the prospective period (N=137), median (interquartile range)/mean ABR was low at 0.5 (0.0-1.2)/0.9. Median (interquartile range) injection frequency and factor consumption were also low with 52.5 (52.2-52.6) injections/year and 2,443 (2,022-2,970) IU/kg/year, respectively. Results were similar since rFIXFc initiation (N=137). Compared to prior SHL prophylaxis (N=92), ABR was reduced/remained low, while injection frequency and factor consumption reduced since rFIXFc initiation. Most physicians (88.5%; 69/78) and patients (90.0%; 90/100) were satisfied/highly satisfied with rFIXFc prophylaxis. B-MORE represents the largest real-world investigation of rFIXFc usage, with up to nearly seven years of follow-up (retrospective and prospective periods). Final data confirm rFIXFc as an effective and well-tolerated long-term prophylactic treatment for hemophilia B.

PMID 43047976
阅读全文 →
PubMedDrugs2026-11-17

Insulin Efsitora Alfa: First Approval.

Blair Hannah A HA

Insulin efsitora alfa (Onswik™) is a once-weekly ultra-long-acting recombinant basal insulin being developed by Eli Lilly and Company for the treatment of diabetes mellitus. Administered once weekly as a subcutaneous injection, insulin efsitora alfa is designed to provide a simplified treatment regimen relative to standard daily basal insulins. On 20 August 2026, insulin efsitora alfa received its first approval in the EU for the treatment of type 2 diabetes mellitus (T2DM) in adults. On 24 September 2026, insulin efsitora alfa was approved in the USA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Insulin efsitora alfa is approved in the EU, Iceland, Norway, Liechtenstein and the USA and is under regulatory review in the UK and Japan for T2DM. This article summarizes the milestones in the development of insulin efsitora alfa leading to this first approval for T2DM.

PMID 43040187
阅读全文 →
PubMedFrontiers in immunology2026-11-17

Immune-epithelial coordination of barrier repair in inflammatory bowel disease: from cell survival to functional healing.

Wu Ben B, He Bin-Sheng BS

Epithelial repair in inflammatory bowel disease involves preservation of viable cells, coverage of wounds, renewal of epithelial populations and recovery of selective transport and secretion. These processes overlap, yet improvement in one does not establish completion of the others. This narrative review examines how immune signals influence these transitions and how experimental repair findings relate to patient outcomes. We first describe the junctional and mucus barrier and the distinction between physiological, endoscopic and histological measurements. We then examine epithelial death control, regenerative pathways and immune-derived signals using studies selected for compartment-specific perturbation, functional measurements or informative discrepancies between experimental and clinical findings. Interleukin-22 illustrates the importance of context: it promotes regeneration in several experimental systems, disrupts barrier function in a human colon chip, and has not yielded demonstrated efficacy as efmarodocokin alfa in a phase II ulcerative colitis trial. In one small infliximab study, paired measurements from nine patients showed an increase in epithelial resistance after treatment. Larger controlled studies are needed to establish how consistently functional recovery accompanies immune control. We organize the evidence around target engagement, epithelial response, barrier function and patient benefit, with example assays and common interpretive pitfalls for each. The resulting synthesis identifies the measurements needed to distinguish protection from repair and to test whether an epithelial effect adds value to effective immune therapy. Clinical studies must ultimately establish that a specified functional improvement is durable and beneficial to patients.

PMID 43041937
阅读全文 →
PubMedMolecular and cellular endocrinology2026-11-16

Preparations of recombinant follicle-stimulating hormone (FSH) alfa and delta induce different intracellular signals in vitro.

Lazzaretti Clara C, Mercanile Giada G, Perri Carmela C, Mascolo Elisa E et al.

Recombinant follicle-stimulating hormone (FSH)-based drugs Rekovelle® and Gonal-F® are produced in different host cell lines, i.e. the genetically modified human fetal retinal cell line (PER.C6®) and Chinese hamster ovary (CHO), respectively. Source cells lead to hormone preparations with distinct glycosylation profiles, possibly impacting the pattern of hormone-mediated intracellular signaling cascades. In this study, we compared the preparation-specific intracellular signaling pattern and receptor internalization in vitro. In transfected HEK293 cells expressing the FSH receptor (FSHR), we found that Rekovelle® is more potent than Gonal-F® in activating dose-dependent intracellular cAMP and CRE promoter activity, as an issue detectable in the nM concentrations range. Interestingly, Rekovelle® had a biphasic behaviour on the cAMP-pathway, since the 1 μM drug concentration (33.3 μg/ml) leads to inhibition of cAMP and CRE response, which did not occur with the equimolar Gonal-F® concentration. This event was accompanied by recruitment of β-arrestin 2 and FSHR routing to the late endosomes. To evaluate whether cAMP and CRE inhibition by 1 μM Rekovelle® depends on FSHR internalization, FSH dose-response experiments were performed in β-arrestin 2 knockout HEK293 cell line, where 1 μM Rekovelle® resulted in an intracellular cAMP increase. In conclusion, we found the mechanism underlying different modes of action between follitropin alfa and delta, as an issue likely linked to different glycan profiles, supporting the rationale for a tailored clinical use of these drugs.

PMID 43039287
阅读全文 →
PubMedTherapeutic advances in rare disease2026-11-16

Patient perspectives of participation in clinical studies in late-onset Pompe disease: Structured exit interviews from cipaglucosidase alfa plus miglustat studies.

Gault Jamie J, Amon Farah F, Clarke Sophie S, Holdbrook Fred F et al.

Cipaglucosidase alfa plus miglustat (cipa+mig) is an approved treatment in many countries for adults living with late-onset Pompe disease. To capture patient insights into clinical studies. We conducted an exit interview study based on the 2022 US Food and Drug Administration (FDA) guidance recommending structured interviews. We conducted structured exit interviews with participants (≥18 years) in the UK or USA who completed the final visit or had data available at the final data cut-off date for three long-term clinical trials (ATB200-02 [NCT02675465], ATB200-04 [NCT03911505], and ATB200-07 [NCT04138277]) and from the cipa+mig UK Early Access to Medicines Scheme (EAMS). Participants were asked to rate their experience with the study conduct, using a two-component therapy, and disease-specific and general quality-of-life (QoL) outcomes. Of 91 eligible participants, 23 (13 male) completed an exit interview (clinical trials n=19; EAMS n=4). For most participants (83%), looking for another treatment option and/or wanting to contribute to drug development was the motivation for joining a study. Almost all participants stated they were provided with appropriate information before joining the study (96%), and the time commitment was acceptable (91%). Most participants (74%) did not find the process of taking the two-component therapy challenging, while the remaining 26% had neutral experiences. Around half (52%) rated the fasting process before taking mig as very convenient or convenient; 39% were neutral, and 9% rated the fasting process as mildly inconvenient. Finally, 57% of participants felt that cipa+mig provided benefits and improved their QoL. Overall, alongside perceived improvements in disease-specific and QoL outcomes, participants found taking the two-component therapy neither challenging nor inconvenient. These exit interviews provide valuable insights into patient perspectives of cipa+mig and study processes not captured using standard patient-reported outcome measures and should be considered in future studies in line with FDA guidance.

PMID 43036470
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多epoetin alfa